At what enterprise value was PHARMATHEN acquired in 2021?

During the acquisition of PHARMATHEN by PARTNERS GROUP in 2021, the transaction's Enterprise Value is estimated to be in the range of 1b - 4b EUR.

What was the EV/EBITDA of PHARMATHEN when it was acquired by PARTNERS GROUP?

The estimated EV/EBITDA multiple for PHARMATHEN is in the range of 15x - 25x.

When was PHARMATHEN acquired by PARTNERS GROUP?

PHARMATHEN was acquired by PARTNERS GROUP in 2021.

What was the revenue of PHARMATHEN at the time of the deal?

The revenue of PHARMATHEN at the time of the deal is estimated to be in the range of 150M - 250M EUR.

What was the EBITDA of PHARMATHEN during the acquisition?

PHARMATHEN's EBITDA is estimated to be in the range of 50M - 100M EUR.

How is the data for the PHARMATHEN acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the PHARMATHEN deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.bcpartners.com/news/bc-partners-sells-pharmathen-to-partners-group/

← DATABASE

Home Database Healthcare & PharmaPHARMATHEN

07/2021

PHARMATHEN acquired by PARTNERS GROUP

GREECE Life Sciences / Pharma & Biotech / CDMO EV 1b - 4b EUR

Context

Partners Group acquired 100% of Pharmathen from BC Partners, which had acquired the company in 2015. During its ownership, BC Partners invested over €250 million in R&D and new FDA-approved production facilities, nearly doubled the employee headcount, and repositioned Pharmathen from a traditional European generics manufacturer into a technology-driven global leader in complex drug delivery. The transaction is expected to support Pharmathen's continued growth, particularly into the US market. BC Partners was advised by Jefferies (financial) and Kirkland & Ellis (legal).

It is worth noting that the fund Bc Partners took control of Pharmathen through an LBO in 2015.

PHARMATHEN, which reported an EBITDA margin of in 2021, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (15.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Pharmathen is a leading European pharmaceutical and drug delivery technology company founded in 1969, specialising in the development and manufacturing of complex "sustained release" drug delivery technologies. The company is the global leader in complex long-acting injectables (LAI) and has established a long-acting therapeutic technologies (LATT) platform, positioning it at the forefront of one of the most technically demanding and high-barrier segments of the pharmaceutical industry. Pharmathen operates a highly differentiated business model combining best-in-class R&D capabilities with FDA-approved manufacturing facilities, serving a blue-chip customer base across nearly 100 countries worldwide.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2021

2020

Other operations with PHARMATHEN

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
06/2015	BC PARTNERS	PHARMATHEN	GREECE	CDMO

REFERENCES

Valuation range: EV 1b - 4b EUR

Revenue range: 150M - 250M EUR

EBITDA range: 50M - 100M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of PHARMATHEN by PARTNERS GROUP are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Acquirer: partners group